Uma Borate, MD
Enriched profileAssociate Professor, Division of Hematology (also cited as Clinical Associate Professor / Acute Leukemia Clinical Research Director) · The Ohio State University
Uma Borate is Associate Professor, Division of Hematology (also cited as Clinical Associate Professor / Acute Leukemia Clinical Research Director) at The Ohio State University. OpenAlex indexes 293 publications with 7,956 citations (h-index 33); ClinicalTrials.gov lists 11 registered studies with this person as an investigator.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Uma Borate, MD, is Associate Professor, Division of Hematology (also cited as Clinical Associate Professor / Acute Leukemia Clinical Research Director) at The Ohio State University (Division of Hematology / OSUCCC – James, James Cancer Hospital and Solove Research Institute), Columbus, OH. The public record shows 293 publications with 7,956 citations (h-index 33), centered on Hematology. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 26 companies.
- Most recent indexed publication: 2026 · Blood advances
- Top research focus: Hematology
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 26 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 11 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Sponsor: National Cancer Institute (NCI)
- Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
Sponsor: SystImmune Inc.
Industry payments
Updated 27 Aug 2026
26 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year202512 payments$10,610openpaymentsdata.cms.gov ↗
- Syndax Pharmaceuticals, Inc.Program year202511 payments
- Incyte CorporationProgram year202512 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor37.1%Jakafi44%Sprycel40%Iclusig15%Part D<11 patientsBCL-2 Inhibitor37.1%Venclexta100%Part D≥18 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Hematologic Responses Achieved with Luspatercept in Higher-Risk Myelodysplastic Syndromes.
Blood advances
Article2026 - Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.
Blood advances
Clinical Trial2025 - Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.
Journal of clinical oncology
Clinical Trial2025 - A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.
Cancer research communications
Clinical Trial2025
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- X / Twitter
x.com/beatalleukemia
Mentions by others
where others cite or feature them- X / Twitter
x.com/OhioStateWIMS/status/1541930176963133440
- YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - X / Twitter
X/Twitter handle @beatalleukemia, bio: "Dr. Uma Borate: Associate Professor"
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MBBS (medical degree)
B.J. Medical College, University of Pune
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗ - M.S.
Pathobiology and Molecular Medicine, University of Cincinnati
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org ↗ - Residency
Albert Einstein Medical Center, Philadelphia
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗ - Fellowship in Hematology/Oncology
University of Alabama
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org ↗
Editorial & leadership roles
journal and society appointments- Disease Group Leader
MDS and MPN Clinical Trial Disease Groups, OSUCCC – James Leukemia Research Program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aamds.org ↗
Awards & honors
honors on the public record- Evans MDS Discovery Research Grant recipient (2022)
for project on targeting the inflammasome in high-risk clonal cytopenia patients to prevent progression to MDS/AML
2022verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →evansmds.org ↗
Secondary affiliations
appointments beyond the home institution- Formerly Oregon Health & Science University (OHSU)
Portland, OR, prior institutional affiliation before move to Ohio State
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →patientpower.info ↗ - Member: Southwest Oncology Group (SWOG)
American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →runx1-fpd.org ↗
Media & interviews
press, podcasts and appearances- "Treatments for MDS and Secondary AML"
video interview with Uma Borate and Jacqueline Garcia, YouTube
2025provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncbrothers.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →patientpower.info ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Ernest Mazzaferri, MD
The Ohio State University
Jennifer Woyach, MD
The Ohio State University
Steven Gabbe, MD
The Ohio State University
Carl Leier, MD
The Ohio State University